IQE FY2025 results analysis: weaker revenue, but the recovery story is starting to show
IQE’s 2025 numbers are not pretty on the surface. Revenue fell to £97.3 million from £118.0 million, adjusted EBITDA dropped to £3.2 million from £8.1 million, and the group stayed loss-making.
But this RNS is really about two things. First, trading improved in the second half of 2025 and that momentum has carried into 2026. Second, the £81 million fundraise changes the balance sheet story in a big way.
| Key figure | FY2025 | FY2024 |
|---|---|---|
| Revenue | £97.3 million | £118.0 million |
| Adjusted EBITDA | £3.2 million | £8.1 million |
| Adjusted EBITDA margin | 3% | 7% |
| Reported loss before tax | £37.0 million | £36.9 million |
| Reported net cashflow from operations | £8.1 million | £1.3 million |
| Cash and cash equivalents | £15.7 million | £4.7 million |
| Adjusted net debt | £31.5 million | £18.8 million |
IQE revenue split shows photonics strength offset by a nasty wireless slump
The standout divide in these results is simple. Photonics was good, wireless was weak.
Photonics revenue rose 15% to £57.1 million, helped by funding releases for certain US military and defence programmes in the second half and continued growth linked to AI and data centres. Wireless revenue fell 40% to £40.1 million, hit by softer mobile handset demand, macro uncertainty in the first half, and customers using existing inventory rather than ordering more.
That mix matters because it tells you where IQE’s growth engine is now. The old dependence on handset-related demand looks less reliable, while photonics – especially Indium Phosphide, or InP, used in optical communications – is becoming the higher-quality growth area.
Profitability was squeezed by underused factories and lower sales
Adjusted EBITDA – a measure of operating profit before interest, tax, depreciation and amortisation, with some one-offs stripped out – fell 60.1% to £3.2 million. The margin shrank to just 3% from 7%.
Management says this was due to a lower revenue base and underutilisation of manufacturing assets and capacity. In plain English, the factories were not busy enough, and that is painful in a capital-intensive business like this one.
There were also significant impairments. IQE booked a £9.6 million impairment loss on intangible assets, plus smaller impairments on property, plant and equipment and right-of-use assets. That is never ideal, because it tells you management has had to reassess the carrying value of parts of the asset base.
IQE cash flow improved, but the year-end balance sheet still looked stretched
One encouraging feature is cash generation from operations. Reported net cashflow from operations improved to £8.1 million from £1.3 million, while adjusted net cashflow from operations rose to £11.2 million from £6.1 million.
That said, the year-end balance sheet still showed pressure. Adjusted net debt worsened to £31.5 million from £18.8 million, even though cash rose to £15.7 million. Net assets also fell sharply to £89.7 million from £134.1 million.
This is why the fundraise matters so much. Without it, investors would be spending most of their time worrying about the capital structure rather than the technology opportunity.
Why the £81 million IQE fundraise is the real turning point
The strategic review has ended with financing rather than a break-up sale, and that looks like the most important takeaway from this announcement. IQE has raised approximately £81.0 million gross, with the proceeds earmarked to repay its existing revolving credit facility with HSBC, support working capital and fund strategic investment.
The headline number is impressive, but the more useful figure is the one management gives after the moving parts are netted off. Following completion of the fundraise and repayment of the HSBC facility, IQE says it will receive net cash inflows of £27.9 million.
- MACOM is investing £45.0 million, made up of £30.0 million of equity and £15.0 million of new non-interest bearing convertible loan notes.
- Existing noteholders are redeeming and reinvesting £23.0 million of convertible loan notes.
- A placing and retail offer raised £13.0 million.
There are two big positives here. First, the balance sheet is materially stronger. Second, MACOM is not just writing a cheque – it has also entered into long-term supply agreements with IQE, which is a useful commercial endorsement.
The trade-off is dilution. New shares have been issued, and existing holders will own a smaller percentage of the company afterwards, although the dilution percentage is not disclosed in this RNS. For most investors, that is a price worth paying if it removes financing risk and gives the business room to grow.
AI photonics demand and defence orders are driving the 2026 IQE outlook
Management’s outlook is clearly more upbeat than the backward-looking 2025 numbers. Trading in Q1 2026 was in line with expectations, with strong demand across all core segments, and IQE says demand for its InP solutions for optical photonics in data centres and AI infrastructure is accelerating.
That is important because this is not vague “green shoots” language. The company is explicitly guiding for revenue growth of more than 20% in FY2026, with strong order book visibility into the second half. It also expects a high-single digit to low double-digit adjusted EBITDA outcome.
If IQE delivers that, the earnings profile could look very different from 2025. The company would move from survival mode towards recovery mode.
Design wins matter, but they are not revenue yet
The business update is packed with design wins, qualifications and development orders across InP photonics, GaN RF, VCSEL sensing, microLED and power electronics. That is strategically encouraging because it shows IQE is active in several attractive markets including AI, aerospace and defence, automotive sensing and advanced displays.
Still, investors should keep a cool head. Design wins are promising, but they are not the same as full-scale profitable volume production. The case for IQE improves if these programmes convert into repeat revenues at decent margins.
What IQE retail investors should like – and what should still worry them
The positives
- Photonics revenue grew to £57.1 million and is now the main source of momentum.
- AI and data centre demand for InP looks like a genuine growth driver.
- The £81.0 million fundraise removes a lot of balance sheet pressure.
- MACOM’s investment and supply agreements strengthen the strategic case.
- FY2026 guidance points to a meaningful rebound.
The negatives
- FY2025 was weak, with revenue down 17.6% and adjusted EBITDA down 60.1%.
- Wireless revenue fell 40%, showing the handset market can still hurt results badly.
- The group remains loss-making, with a reported loss before tax of £37.0 million.
- Impairments and restructuring continue to drag on reported performance.
- Shareholder dilution is part of the rescue package, even if the exact percentage is not disclosed here.
My view on IQE after the FY2025 results and strategic review
I think this RNS is more positive than the 2025 headline numbers suggest. The historic figures show a company that had real pressure on profits and the balance sheet, but the post-year-end financing and the 2026 guidance suggest the worst of that pressure may be passing.
The key question now is execution. IQE needs to turn AI photonics demand, defence strength and design wins into sustained revenue growth and much better profitability. If it does, this fundraise will look like the point where the story reset. If it does not, investors will just remember the dilution and the long list of restructuring charges.
For now, this looks like a repaired balance sheet attached to a business with credible exposure to some very attractive semiconductor niches. That is a much better place to be than where IQE started the year.
